OUP user menu

The gut microbiome as novel cardio-metabolic target: the time has come!

Sarah Vinjé , Erik Stroes , Max Nieuwdorp , Stan L. Hazen
DOI: http://dx.doi.org/10.1093/eurheartj/eht467 883-887 First published online: 11 November 2013


Recent studies reveal a potential contribution of intestinal microbes in the expression of certain human cardio-metabolic diseases. The mechanisms through which intestinal microbiota and/or their metabolic products alter systemic homoeostasis and cardio-metabolic disease risks are just beginning to be dissected. Intervention studies in humans aiming to either selectively alter the composition of the intestinal microbiota or to pharmacologically manipulate the microbiota to influence production of their metabolites are crucial next steps. The intestinal microbiome represents a new potential therapeutic target for the treatment of cardio-metabolic diseases.

  • Gutmicrobiota
  • Vascular inflammation
  • Atherothrombosis
  • Insulin resistance
  • Obesity
  • TMAO
  • Therapy
View Full Text

Sign In

ESC members Follow the 'ESC Member and Congress Delegate Sign In' link below for free online access if your subscription to this journal is via the European Society of Cardiology, either as a member or an ESC Congress delegate. Discover if you are an ESC member here.

Otherwise, if your subscription is via OUP, enter your OUP username and password, or select an alternative sign in option below.

Log in through your institution